If tirzepatide's dual-agonist approach interests you, check does tirzepatide burn fat for a mechanistic comparison
People should not treat it as a routine medication unless it has an approved, regulated pathway in their jurisdiction
References SURMOUNT-5 head-to-head trial (NEJM, May 2025) summary via American College of Cardiology: SURPASS-2 primary publication (NEJM, 2021): Eli Lilly SURMOUNT-1 results announcement (NEJM data): Insights into the Mechanism of Action of Tirzepatide (PMC narrative review): Tirzepatide is an imbalanced and biased dual GIP/GLP-1 receptor agonist (PMC): SURMOUNT-5 GI tolerability / discontinuation data (Applied Clinical Trials, tctmd, DiabetesontheNet coverage): SURMOUNT-1 to -4 GI tolerability (Rubino 2025, Diabetes Obesity & Metabolism): Community sentiment context Reddit GLP-1 side-effect analysis and comparative meta-analyses (PMC): Research Use Only Notice: The content on this page is provided for informational and educational purposes only
To view a copy of this licence, visit About this article Cite this article Khare, S., Osumili, B., Debackere, N
The goal is substantial settlement amounts that reflect not just immediate medical expenses, but lifetime consequences of permanent injuries
